DENOSUMAB ASSOCIATED WITH BONE DENSITY INCREASE  AND CLINICAL IMPROVEMENT IN A LONG-TERM HEMODIALYSIS  PATIENT. CASE REPORT AND REVIEW OF THE LITERATURE

Dusilová Sulková, Sylvie; Horáček, Jiří; Šafránek, Roman; Gorun, Petr; Viklický, Ondřej; Palička, Vladimír

doi:10.14712/18059694.2014.6

Acta Medica > Archive > 2014, Vol. 57 > Issue 1 > DENOSUMAB ASSOCIATED WITH BONE DENSITY…

Acta Med. 2014, 57: 30-33

https://doi.org/10.14712/18059694.2014.6

DENOSUMAB ASSOCIATED WITH BONE DENSITY INCREASE AND CLINICAL IMPROVEMENT IN A LONG-TERM HEMODIALYSIS PATIENT. CASE REPORT AND REVIEW OF THE LITERATURE

Sylvie Dusilová Sulková^a,b, Jiří Horáček^c, Roman Šafránek^b,d, Petr Gorun^e, Ondřej Viklický^f, Vladimír Palička^g

^aDepartment of Internal Medicine II, Charles University, Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic
^bHemodialysis Centre, University Hospital Hradec Kralové, Czech Republic
^cDepartment of Internal Medicine IV, Charles University, Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic
^dDepartment of Internal Medicine III, Charles University, Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic
^eHemodialysis centre BBraun Avitum, Ústí nad Orlicí, Czech Republic
^fDepartment of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
^gDepartment of Clinical Biochemistry, Charles University, Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic

Denosumab is a human monoclonal antibody representing a novel therapy of osteoporosis. Contrary to always other antiosteoporotic drugs, it is not contraindicated in advanced chronic kidney disease, as its pharmacokinetic does not differ from patients with normal kidney function. However, published case reports in chronic kidney disease (CKD) patients stopped the therapy after single dose because of hypocalcemia. We present a case of successful treatment of osteoporosis in a young hemodialysis patient with repeated denosumab doses.